TKTimothy J. Key

Timothy J. Key

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Timothy J. Key has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women

    by Ruth C. Travis, Michael Churchman, Sarah A. Edwards, Gillian Smith, Pia K. Verkasalo, C. Roland Wolf, Helga Wolf, Timothy J. Key

    The production of endogenous estradiol, and thus the risk of breast cancer, may be affected by functional polymorphisms in the genes coding for enzymes in the steroid biosynthesis pathway. Potentially important polymorphisms have been identified in three genes: CYP17, which encodes for a P450 enzyme that catalyzes 17α-hydroxylase and C17-20 lyase activities in the biosynthesis of androgens; CYP19, which encodes for aromatase, the enzyme involved in the conversion of androgens to estrogens; and HSD17-B1, which encodes for the 17β-hydroxysteroid oxidoreductase type 1 enzyme that reduces estrone to estradiol. Several studies have observedan association between risk for breast cancer and these polymorphisms (1). However, other studies have not found such an association, and the biological relationship of these polymorphisms with circulating estrogens has yet to be established. We assessed whether polymorphisms in CYP17, CYP19, or HSD17-B1 are associated with circulating levels of estradiol, the most biologically potent estrogen. Specifically, we examined a T to C substitution 34 bp upstream of the translation initiation site in the 5′ untranslated region of CYP17 among 634 premenopausal and 455 postmenopausal British women. Among the postmenopausal women, we also examined a [TTTA]n repeat allele beginning at bp 682 (intron 4) of CYP19, an associated TCT insertion/deletion polymorphism, a C to T substitution in the untranslated region of exon 10 of CYP19, and an A to G substitution in exon 6 of HSD17-B1 1,954 bp downstream of the first nucleotide in the translation initiation codon.Study participants included 636 premenopausal and 456 postmenopausal British women recruited to the Oxford arm of the European Prospective Investigation into Cancer and Nutrition and previously studied in a cross-sectional analysis of sex hormones and risk factors for breast cancer (2, 3). Details of the estradiol assays are described elsewhere (2). One postmenopausal and two premenopausal women were excluded from the current study due to insufficient buffy coat being available for molecular analyses.Genotyping on DNA extracted from buffy coat samples was conducted blind after the hormone assays had been completed. Eight hundred and ninety-eight samples were genotyped at the Cancer Research UK Genotyping Facility in Oxford. Blinded quality control samples (3.4%) were inserted to validate genotype identification procedures: concordance for the blinded samples was 100% for the CYP17 assay, 93.3% for the CYP19 intron 4 assay, 100% for the CYP19 exon 10 assay, and 100% for the HSD17-B1 assay. One hundred and ninety-eight samples were genotyped for the CYP17 single nucleotide polymorphism at the Biomedical Research Centre in Dundee as part of a previous unpublished study using similar methods. Genotype frequencies from the two laboratories were statistically similar: CYP17 TT, TC, and CC genotype frequencies were 40.0%, 45.9%, and 14.1%, respectively, for samples assayed in Oxford and 38.4%, 47.0%, and 14.7%, respectively, for samples assayed in Dundee (χ2 = 0.18, P = 0.9). Seven samples were genotyped for CYP17 at both laboratories and there was 100% concordance between the two sets of results.Estradiol values were logarithmically transformed to reduce the positive skewness of the distributions, and geometric mean hormone values and the corresponding95% confidence intervals are presented. ANOVA was used to evaluate the association between genotypes andestradiol concentrations. Estradiol concentrations in postmenopausal women, classified by their number of putative high-risk alleles, including single nucleotide polymorphisms in CYP17, CYP19 exon 10, and HSD17-B1 were also examined. Statistical analyses were repeated with adjustment for potential confounders including age (5-year age groups), body mass index [calculated as weight/height2 (kg/m2) and grouped <20, 20<22.5, 22.5<25, 25<27.5, ≥27.5], vigorous exercise (0, 1-2, 3-4, ≥5 hours per week), and number of days the blood sample was in the post (0-1, 2, ≥3 days; among postmenopausal women only). In the analyses of data from premenopausal women, adjustment was also made for stage of menstrual cycle (early follicular, late follicular, mid-cycle, early luteal, and late luteal defined as ≥22, 16-21, 12-15, 3-11, and 0-2 days before next menstrual period), smoking status (never, former, current), alcohol consumption (<0.50, 0.50<8.0, 8.080% power at a 0.05 significance level to detect differences of 25% in plasma concentrations between women with different genotypes. The results suggest that there is no large effect of the polymorphisms studied in CYP17, CYP19, and HSD17-B1 on endogenous estradiol concentrations; however, more data would be needed to establish whether or not there is a small effect.


    • 1 August 2003
      • Vol. 12  (8) , 806-8

    Reproducibility over 5 years of measurements of 6-sulphatoxymelatonin in urine samples from postmenopausal women.

    by Ruth C Travis, Naomi E Allen, Petra H M Peeters, Paul A H Van Noord, Timothy J Key

    To assess the appropriateness of a single measurement of urinary 6-sulfatoxymelatonin (aMT6S) as a marker for long-term exposure to endogenous melatonin in epidemiological studies, we examined the reproducibility of aMT6S in first morning urine voids collected from 40 postmenopausal women. Urine specimens were collected on three different occasions, and the mean time between the first and the third urine sample was 5.1 years. Urinary aMT6S levels were measured by radioimmunoassay and adjusted for creatinine. The intraclass correlation for aMT6S adjusted for creatinine was 0.56 (95% confidence interval, 0.39-0.73). The classification of aMT6S concentrations in first morning voids from postmenopausal women appears to be sufficiently reproducible to justify its use as a marker for long-term exposure to melatonin in epidemiological studies.


    • 1 June 2003
      • Vol. 12  (6) , 578-81

    Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.

    by Naomi E Allen, Juergen Reichardt, Hannah Nguyen, Timothy J Key

    Androgens are essential for the growth of the prostate gland and have been implicated in the development of prostate cancer. Little is known about the determinants of androgen levels in men, although observed ethnic differences suggest they may have a genetic basis. Several polymorphisms have been identified in the steroid 5 alpha-reductase type II gene (SRD5A2), which encodes an enzyme that catalyzes the conversion of testosterone to its more potent metabolite, dihydrotestosterone. Although some of these polymorphisms have been associated with increased prostate cancer risk, the association with circulating androgen levels remains unclear. The purpose of this study is to investigate the association between the (TA)(n) dinucleotide repeat polymorphism in the 3' untranslated region and the A49T polymorphism (which replaces the normal alanine with threonine at codon 49) in the SRD5A2 gene and serum androgen concentrations in 604 British men. In particular, we wanted to test the hypotheses that the variant alleles are associated with an increased serum concentration of androstanediol glucuronide, a direct metabolite of dihydrotestosterone and a serum marker of 5 alpha-reductase activity. Mean hormone concentrations were evaluated in each genotype, and adjusted for age and other relevant factors. We found no evidence that the SRD5A2 (TA)(n) repeat polymorphism was associated with androgen levels. Men who possessed one or two copies of the variant T allele in the A49T polymorphism had a significantly 24% lower androstanediol glucuronide concentration than men who were homozygous for the wild-type allele (P = 0.0003). Because of the rarity of this variant allele, larger studies are needed to additionally clarify the role of the A49T polymorphism in androgen metabolism.


    • 1 November 2002
      • Vol. 11  (11) , 1441-8

    The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans.

    by Naomi E Allen, Paul N Appleby, Gwyneth K Davey, Rudolf Kaaks, Sabina Rinaldi, Timothy J Key

    The lower rates of some cancers in Asian countries than in Western countries may be partly because of diet, although the mechanisms are unknown. The aim of this cross-sectional study was to determine whether a plant-based (vegan) diet is associated with a lower circulating level of insulin-like growth factor I (IGF-I) compared with a meat-eating or lacto-ovo-vegetarian diet among 292 British women, ages 20-70 years. The mean serum IGF-I concentration was 13% lower in 92 vegan women compared with 99 meat-eaters and 101 vegetarians (P = 0.0006). The mean concentrations of both serum IGF-binding protein (IGFBP)-1 and IGFBP-2 were 20-40% higher in vegan women compared with meat-eaters and vegetarians (P = 0.005 and P = 0.0008 for IGFBP-1 and IGFBP-2, respectively). There were no significant differences in IGFBP-3, C-peptide, or sex hormone-binding globulin concentrations between the diet groups. Intake of protein rich in essential amino acids was positively associated with serum IGF-I (Pearson partial correlation coefficient; r = 0.27; P < 0.0001) and explained most of the differences in IGF-I concentration between the diet groups. These data suggest that a plant-based diet is associated with lower circulating levels of total IGF-I and higher levels of IGFBP-1 and IGFBP-2.


    • 1 March 2002
      • Vol. 11  (3) , 319-20

    Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene.

    by Naomi E Allen, Gwyneth K Davey, Timothy J Key, Shiyu Zhang, Steven A Narod


  • Top Cited Papers

    Epidemiology of breast cancer

    by Timothy J Key, Pia K Verkasalo, Emily Banks


  • Energy balance and cancer: the role of sex hormones

    by Timothy J. Key, Naomi E. Allen, Pia K. Verkasalo, Emily Banks

    Energy balance can affect the risk for hormone-related cancers by altering sex hormone levels. Energy intake and expenditure are difficult to measure in epidemiological studies, but a chronic excess of intake relative to expenditure leads to a high BMI, which can be accurately measured. In premenopausal women obesity has little effect on the serum concentration of oestradiol, but causes an increase in the frequency of anovular menstrual cycles and thus a reduction in progesterone levels; these changes lead to a large increase in the risk for endometrial cancer, but little change, or a small decrease, in the risk for breast cancer. In post-menopausal women oestradiol levels are not regulated by negative feedback, and obesity causes an increase in the serum concentration of bioavailable oestradiol; this factor causes increases in the risk for both endometrial cancer and breast cancer. The development of ovarian cancer appears to be related more strongly to the frequency of ovulation than to direct effects of circulating levels of sex hormones, and BMI is not clearly associated with the risk for ovarian cancer. In men, increasing BMI has little effect on bioavailable androgen levels, and any effect of obesity on prostate cancer risk is small.


  • Open Access

    Endogenous hormones and the aetiology of breast cancer

    by Timothy J Key, Pia K Verkasalo


  • Open Access

    Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies

    by Timothy J Key, Gary E Fraser, Margaret Thorogood, Paul N Appleby, Valerie Beral, Gillian Reeves, Michael L Burr, Jenny Chang-Claude, Rainer Frentzel-Beyme, Jan W Kuzma, et al.

    We combined data from 5 prospective studies to compare the death rates from common diseases of vegetarians with those of nonvegetarians with similar lifestyles. A summary of these results was reported previously; we report here more details of the findings. Data for 76172 men and women were available. Vegetarians were those who did not eat any meat or fish (n = 27808). Death rate ratios at ages 16–89 y were calculated by Poisson regression and all results were adjusted for age, sex, and smoking status. A random-effects model was used to calculate pooled estimates of effect for all studies combined. There were 8330 deaths after a mean of 10.6 y of follow-up. Mortality from ischemic heart disease was 24% lower in vegetarians than in nonvegetarians (death rate ratio: 0.76; 95% CI: 0.62, 0.94; P < 0.01). The lower mortality from ischemic heart disease among vegetarians was greater at younger ages and was restricted to those who had followed their current diet for >5 y. Further categorization of diets showed that, in comparison with regular meat eaters, mortality from ischemic heart disease was 20% lower in occasional meat eaters, 34% lower in people who ate fish but not meat, 34% lower in lactoovovegetarians, and 26% lower in vegans. There were no significant differences between vegetarians and nonvegetarians in mortality from cerebrovascular disease, stomach cancer, colorectal cancer, lung cancer, breast cancer, prostate cancer, or all other causes combined.


  • Open Access

    Health benefits of a vegetarian diet

    by Timothy J. Key, Gwyneth K. Davey, Paul N. Appleby

    Compared with non-vegetarians, Western vegetarians have a lower mean BMI (by about 1 kg/m2), a lower mean plasma total cholesterol concentration (by about 0.5 mmol/l), and a lower mortality from IHD (by about 25 %). They may also have a lower risk for some other diseases such as constipation, diverticular disease, gallstones and appendicitis. No differences in mortality from common cancers have been established. There is no evidence of adverse effects on mortality. Much more information is needed, particularly on other causes of death, other morbidity including osteoporosis, and long-term health in vegans. The evidence available suggests that widespread adoption of a vegetarian diet could prevent approximately 40 000 deaths from IHD in Britain each year.